During the past decade, CHU de Nantes Hôtel-Dieu conducted 278 clinical trials. In the 10-year time frame, 278 clinical trials started and 99 clinical trials were completed, i.e. on average, 35.6% percent of trials that started reached the finish line to date. In the past 5 years, 136 clinical trials started and 68 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

Out of the total clinical trials conducted in "CHU de Nantes Hôtel-Dieu" #1 sponsor was "Janssen Research & Development, LLC" with 32 trials, followed by "Celgene" with 22 trials sponsored, "The Lymphoma Academic Research Organisation" with 22 trials sponsored, "Pfizer" with 21 trials sponsored and "Gilead Sciences" with 21 trials sponsored. Other sponsors include 334 different institutions and companies that sponsored additional 158 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "CHU de Nantes Hôtel-Dieu" #1 collaborator was "Bristol-Myers Squibb" with 7 trials as a collaborator, "Ministry of Health, France" with 7 trials as a collaborator, "AbbVie" with 6 trials as a collaborator, "Roche Pharma AG" with 6 trials as a collaborator and "Celgene" with 5 trials as a collaborator. Other collaborators include 209 different institutions and companies that were collaborators in the rest 157 trials.

According to Clinical.Site data, the most researched conditions in "CHU de Nantes Hôtel-Dieu" are "Multiple Myeloma" (38 trials), "HIV Infections" (13 trials), "Ulcerative Colitis" (13 trials), "Myelodysplastic Syndromes" (12 trials) and "Acute Myeloid Leukemia" (11 trials). Many other conditions were trialed in "CHU de Nantes Hôtel-Dieu" in a lesser frequency.

Most popular intervention types in "CHU de Nantes Hôtel-Dieu" are "Drug" (355 trials), "Other" (56 trials), "Biological" (26 trials), "Procedure" (24 trials) and "Device" (18 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (77 trials), "Dexamethasone" (22 trials), "Rituximab" (20 trials), "Lenalidomide" (13 trials) and "Cyclophosphamide" (12 trials). Other intervention names were less common.

The vast majority of trials in "CHU de Nantes Hôtel-Dieu" are 425 trials for "All" genders, 14 trials for "Male" genders and 9 trials for "Female" genders.

Currently, there are 169 active trials in "CHU de Nantes Hôtel-Dieu". 5 are not yet recruiting, 89 are recruiting, 74 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 205 completed trials in CHU de Nantes Hôtel-Dieu, undefined suspended trials, and 48 terminated clinical trials to date.

Out of the total trials that were conducted in CHU de Nantes Hôtel-Dieu, 44 "Phase 1" clinical trials were conducted, 127 "Phase 2" clinical trials and 207 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 16 trials, and there were also 38 trials that are defined as “Not Applicable".

CHU de Nantes Hôtel-Dieu has several departments that took part in Clinical trials: "CHU Nantes - Hôtel Dieu/Service d'Hématologie Clinique" - 25 trials, "Hematology Dpt, Hopital de l'Hotel Dieu" - 5 trials, "Hopital Hotel Dieu Et Hme; Hepatologie Gastro Enterologie" - 2 trials